Pretanib®
Nilotinib
Acción terapéutica
Tyrosine kinase inhibitor.
Indicaciones
- First-line treatment of Ph+ CML in chronic phase in adults and children over 2 years of age.
- Treatment of Ph+ CML in chronic and accelerated phases in adults with resistance to prior therapies.
Presentación
150 mg. and 200 mg. 120 hard capsules